Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19.
Si-Hyuck KangDong-Hoon LeeKyung Do HanJin- Hyung JungSang-Hyun ParkAndrew M DaiHenry G WeiChang-Hwan YoonChang Hwan YoonIn-Ho ChaeCheol-Ho KimPublished in: Clinical hypertension (2021)
Patients with hypertension had worse COVID-19 outcomes than those without hypertension, while the use of RAAS-blocking agents was not associated with increased risk of any adverse study outcomes. The use of ACE inhibitors or ARBs did not increase the risk of adverse COVID-19 outcomes, supporting current guidance to continue these medications when indicated.